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The pioneering Times
Although the concept of Transplantation 
could be traced back as early as Saint Cosmas 
and Damian most famous miracle, grafting 
of a leg to replace a patient’s ulcered leg, it 
is not before the 50’s that it entered reality. 
Important steps were made before, from sew-
ing vessels to understanding the basis of the 
major histocompatibility complex (MHC) in 
mice (Snell, 1986). This medical field was pio-
neered in renal transplantation with nearly 
concomitant attempts in Paris, London, 
Edinburgh, Boston. The first successful 
attempt was carried out in Boston by Joseph 
Murray in 1954. The donor and recipient were 
identical twins, showing indeed the impor-
tance of Genetic compatibility. Organ trans-
plantation (OT) then became one of the most 
exciting “success story” of modern Medicine, 
admixing advances in Surgery and intensive 
care Medicine, Immunology, Genetics, and 
Pharmacology. The crucial point was first 
to avoid acute graft rejection which quickly 
appeared to be immune-mediated. The 
development of potent immunosuppressive 
(IS) drugs (corticosteroids, calcineurin inhib-
itors) opened the way to clinical transplanta-
tion. Most critical landmarks were in 1957 
the first hepatic transplantation followed by 
transplantation of other organs, in 1967 the 
first successful heart transplantation, lung 
(1968), trachea (1979), pancreas, and more 
recently hands (2000) and facial tissue (2005). 
In hematopoietic stem-cell transplantation 
(HSCT), the initial report of the use of bone 
marrow transplantation in cancer treatment 
was made by Thomas in 1957. Several Nobel 
prizes were awarded to some of the trans-
plantation “founding fathers”: Medawar and 
Burnet (1960), Benacerraf, Dausset and Snell 
(1980), Murray and Thomas (1990).
TransplanTaTion medicine and 
The golden age of hla
It is a remarkable that HLA, the human 
MHC, discovery was due to a deliberate 
medical action, transplantation, and not 
to a naturally occurring disease. Actually, 
if HLA governs the allogeneic response, it 
is obviously not its primary function. HLA, 
discovered in the 50’s in Dausset, van Rood, 
and Mc Devitt laboratories, among others, 
appeared from the 70’s onward as a central 
actor of the immune response. MHC mol-
ecules bind peptides from antigens (of viral, 
tumoral, or “self” origin) to be presented to 
the T-cell antigen receptor. This has been 
definitely evidenced by several crystallo-
graphic structures of MHC– peptide com-
plexes, the first being the HLA-A2 molecule 
binding endogenous peptides by Bjorkman 
in the Wiley’s laboratory. The role of HLA is 
therefore to bind peptides from foreign pro-
teins and then be recognized, as a combina-
tion, by T cells that ensure the elimination 
of the source of peptide. It appears clearly 
how this system could be efficient to rec-
ognize self from “allogeneic” non-self, i.e., 
cells or tissues from another individual of 
the same species but with a different genetic 
background and a different array of HLA–
peptide complexes. Indeed, the frequency 
of alloreactive naïve T cells is about 100 to 
1000-fold higher than that of naïve conven-
tional T cells. This dramatically efficient sys-
tem has to be kept under control to avoid 
graft rejection. In HSCT, a situation where 
a lymphopenic host receives an appropriate 
conditioning regimen (total body irradia-
tion, chemotherapy) to accept the alloge-
neic source of cells, the risk is to develop a 
potentially fatal “graft-versus-host” (GVH) 
reaction, based on the same concept of 
allogeneic reactivity but directed toward 
the recipient self antigens. Considerable 
advances have been made following these 
basic discoveries:
© In histocompatibility and immunoge-
netics, leading to the definition of more 
than 4000 HLA alleles. Technically, 
HLA typing evolved from serology to 
Molecular Biology including now high 
speed sequencing. In the meantime, 
besides classical HLA loci (HLA-A, -B, 
-C, -DR, -DP, DQ), others were descri-
bed in the HLA locus (HLA-G, -E, 
MICA, MICB) raising the issue of their 
role in Transplantation Immunology.
© In Pharmacology, with the development 
of new IS drugs (mycophenolate mofe-
til, mTOR inhibitors) and Biotherapies: 
rabbit antithymocyte globulin, mono-
clonal antibodies directed toward the 
interleukin-2 receptor alpha-chain 
(daclizumab and basiliximab) or speci-
fic for CD52 (alemtuzumab).
© In the clinical management of the 
patients and of the drugs with some-
times severe adverse events, especially 
infections and cancer.
All these progresses combined explain 
the development of this highly specialized 
medical field, giving hope to many patients 
affected by an end-stage organ failure or a 
fatal hematological malignancy.
challenges in TransplanTaTion 
immunology and medicine: 
“increase, improve, innovaTe”
These few preliminary remarks show that 
from the very beginning, Transplantation 
was a remarkable integration of Medicine 
and basic Immunology, Pharmacology, 
Epidemiology, and Ethics, to name only 
the most relevant fields. In many ways, 
Transplantation was a leading force of 
innovation in unrelated medical specialties 
and vice versa. Which are some of the main 
limitations we are facing today?
increase TransplanT efficiency and 
donor allocaTion
Around 300,000 Europeans are living with 
a transplanted organ in 2010. Number of 
transplants in Western countries showed a 
45% increase since 2000. In parallel, there is 
an increasing shortage of organ donors and 
thousands are on waiting lists to get trans-
planted. This foster access to living related 
donors and leads to allow more frequently 
organs with a “border line” functionality. 
In the same time, recipients may already 
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have received a successful transplant and 
need to be re-transplanted. Their age tend 
to increase, as well as other risk factors com-
mon to Western aging populations (obe-
sity, infections). In total, this may impair 
the future success rate of OT and pushes to 
improve the definition of genetic match-
ing for an optimal organ allocation. Pre-
transplant status of the recipient in terms 
of HLA pre-sensitization, HLA matching 
or “authorized” mismatching based on sci-
entific algorithms (Duquesnoy, 2011), data 
analysis from broad sequencing to define 
more relevant genetic polymorphisms 
(Pharmacogenetics, non-classical HLA 
polymorphisms, cytokine, and chemokine 
gene polymorphisms) are some of the tasks 
in OT and HSCT as well (Dickinson, 2008). 
In HSCT, the issue is also to optimize donor 
allocation and to further develop alternative 
sources of stem cells already clinically vali-
dated (hematopoietic stem cells from cord 
blood, MHC Haploidentical sibling donor) 
combined with changes in the procedures 
of conditioning (non-myeloablative versus 
myeloablative). This, of course, will require 
large-scale evaluations in terms of clinical 
benefit, in the short (acute GVH disease, 
leukemic relapse) and in the long-term 
(immune recovery, chronic GVH).
improve long-Term survival of 
TransplanTed paTienTs
After the successful step of early graft 
acceptance due to heavy IS, the main issue 
is now more to improve the long-term sur-
vival of solid-organ transplanted patients. 
Maintenance of IS therapy, especially 
calcineurin inhibitors, is associated with 
significant risks of cardiovascular disease, 
metabolic syndrome, bone loss, opportun-
istic infections, and an increased rate of 
malignancies. Similar issues apply to late 
side effects in allo-HSCT patients (Tichelli 
et al., 2009). This would require:
© A better understanding of Tolerance 
in this clinical setting and especially 
of so-called “operational tolerance.” 
Tolerance is the focus of the Frontiers 
Specialty journal “Immunological 
Tolerance,” showing how much the field 
evolved in the past 10 years. Operational 
Tolerance, which is “Holy Grail” of 
transplant immunologists, refers to a 
situation of long-term acceptance of 
transplanted organs without requi-
rement of indefinite IS. This concept 
has been documented in renal tran-
splantation in rare cases where patients 
discontinued their treatment (Saggo 
et al., 2010). It is more common in liver 
Transplantation (Levitsky, 2011) which 
may provide a good “proof of concept” 
of it. However, there is yet no consen-
sus on when and how IS therapy could 
be resumed. This highlights the neces-
sity to define clinically applicable bio-
markers of operational tolerance and 
moreover tolerogenic IS conditions. In 
that view, conceptual advances in the 
regulatory networks of the expanding 
list of CD4 T-cell subsets: “natural” 
regulatory T cells or Treg but also Th17, 
Th22, Th10. Technological advances 
(multiparametric flow cytometry and 
cell-sorting, transcriptomic, and other 
“-omics” signatures) applied to tran-
splanted patient’s follow-up will be of 
great value, in OT (Brouard et al., 2011) 
and HSCT as well.
© Understanding the risk of emer-
gence of malignancies in transplanted 
patients. In OT, cutaneous cancers but 
also post-transplant lymphoprolife-
rative diseases (PTLD) are frequen-
tly associated with heavy IS and in 
most cases virally induced. A better 
knowledge of the immune status of the 
patients could help to predict cancer 
occurrence and to personalize the IS 
regimen. For instance, some IS drugs 
(such as mTOR inhibitors) seem to 
carry a lower risk of secondary mali-
gnancy. Same concepts could apply to 
other late side effects, for instance car-
diovascular or metabolic disorders, in 
OT and HSCT as well.
© In allo-HSCT, improving donor allo-
cation by alternative donor sources is 
already in the Clinics (Haplo-HSCT, 
double cord blood transplantation). 
It gives a chance to patients lacking a 
suitable donor from unrelated donors 
registries. Indeed, it is now commonly 
accepted that cord blood transplanta-
tion could be less stringent in terms of 
HLA matching. However, this should 
be evaluated further at an allelic HLA 
typing level. It will also require more 
tailored prospective viral and immune 
monitoring strategies according to the 
setting of the transplant (source of 
stem cells, conditioning, T-cell deple-
tion…), the recipient pre-transplant 
immune status such as herpes viruses 
positivity (CMV or EBV) or thymic 
function and post-transplant events. 
Besides, relapse remains a major cause 
of failure in allo-HSCT. This explains 
the attempts to boost anti-leukemic 
immune responses by vaccination or 
cellular immunotherapy.
innovaTe: TransplanTaTion as a 
plaTform for immunoTherapy, gene 
Therapy, and regeneraTive medicine
The paradigm of allogeneic responses and 
tolerance acquisition and maintenance is 
getting a new perspective since the devel-
opment of stem-cell-based regenerative 
Medicine. Different aspects should be taken 
into consideration:
© Cell-based Immunotherapies to induce 
Tolerance and improve transplant 
success:
Ø Use of regulatory T cells (Tregs), so-
called “regulatory” dendritic cells or 
mesenchymal stem cells endowed 
with immunosuppressive proper-
ties. These approaches are already 
entering into the Clinics. Extending 
their use will need to find to a pro-
per balance between “beneficial” and 
“detrimental” immunosuppression, 
in other words to derive alloantigen-
specific suppression keeping intact 
the response to third-party pathogen 
and tumor antigens.
Ø Improve immune reconstitution and 
especially thymic function regenera-
tion in allo-HSCT to generate a pool 
of naïve competent T cells (Krenger 
et al., 2011).
Ø To improve transplant success by 
adoptive cellular Therapy:
ü With viral or tumor-specific-spe-
cific donor derived or allogeneic 
third- party T cells.
ü With NK cells, based on the KIR/
ligand mismatch concept (Velardi, 
2008), to prevent or cure leukemic 
relapse. Some successful attempts 
pave the way to large-scale multi-
centric clinical trials.
© Genetic engineering in Transplantation:
Ø In allo-HSCT for hematological mali-
gnancies, gene transfer approaches 
could be a powerful way to selectively 
modulate patient-specific alloreac-
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tivity and anti-tumor responses and 
prevent or control GVHD. Suicide 
gene therapy is to date the most 
advanced approach already imple-
mented in phase I–II clinical trials 
(Ludo-Stanghellini et al., 2010).
Ø In OT, xenotransplantation could 
be an attractive way to circumvent 
donor availability (Le Bas-Bernardet 
et al., 2008). Genetic engineering 
of the donor aims at overcoming 
xenogeneic barriers by inactivating 
species-specific genes (such as pig 
alpha1,3-galactosyltransferase) to 
reduce complement activation and 
humoral acute immune responses. 
Finally, cell-mediated rejection would 
require similar approaches as above to 
be kept under control.
© Regenerative medicine and alloge-
nicity: human pluripotent stem cells 
(PSCs) include embryonic stem cells 
(ESCs) and induced PSCs. They are 
potentially an unlimited source of cells 
for regenerative medicine, i.e., to repair, 
restore, maintain or enhance organ 
function. ESCs express reduced levels 
of MHC class I molecules and non-
MHC class II or costimulatory molecu-
les and could be “immune -privileged.” 
Actually, beyond major obstacles in 
Safety (tumorigenicity, genetic stability, 
cell differentiation) and Ethics, their 
allogenicity, especially in terminally 
differentiated cells and tissues, will 
remains a serious concern (Charron 
et al., 2009).
In summary, advancing such challenges 
could improve access to transplantation and 
the quality of life of transplanted patients 
in the long-term. Moreover, besides the 
topics discussed above, transplantation 
is also tightly connected to Ethics, Social 
Sciences, and Health Economics which 
are crucial to provide an equal access to 
transplantation in minorities and develop-
ing countries.
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